甲磺酸伊马替尼治疗胃肠道间质瘤的研究进展  

The research progress of imatinib mesylate on gastrointestinal stromal tumor

作　　者：高英杰[1] 杨娟[1] 孙姗姗[1] 韩竞春[1] 

机构地区：[1]大连大学附属新华医院肿瘤科,辽宁大连116021

出　　处：《现代肿瘤医学》2014年第9期2248-2251,共4页Journal of Modern Oncology

摘　　要：胃肠道间质瘤(GIST)是胃肠道及腹腔最常见的间叶源性肿瘤,对常规的放疗、化疗均不敏感。外科手术是局限性GIST患者的主要治疗方式,但术后复发率较高。对于术前、术后辅助、复发、转移及不能手术切除的患者,酪氨酸激酶抑制剂甲磺酸伊马替尼对其有较好的治疗效果。本文对甲磺酸伊马替尼治疗胃肠道间质瘤的研究进展作一综述。Gastrointestinal stromal tumor(GIST)is the most common mesenchymal malignancy of the gastrointestinal tract and abdominal cavity.It is unresponsive to standard chemotherapy and to radiotherapy.The main treatment is surgery for limitations of GIST patients,but the postoperative recurrence rate of GIST patients is higher,for preopera-tive,postoperative adjuvant,recurrence,metastasis and not surgical resection of the GIST patients.Tyrosine kinase in-hibitor imatinib mesylate has good effect.This article will review the research progress of imatinib mesylate on gastro-intestinal stromal tumor.

关 键 词：胃肠道间质瘤 甲磺酸伊马替尼 分子靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]